home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.220 +0.010 (+0.83%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Pliant Therapeutics to Participate in Upcoming Investor Events

March 01, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Novartis Takes Down $80M NASH Pact With Pliant Therapeutics ↗

February 24, 2023

Via Benzinga

Pliant Therapeutics to Participate in Upcoming Investor Events

February 07, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

February 02, 2023

Phase 1 clinical study initiation expected in the second quarter of 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Why Pliant Therapeutics Stock Is Skyrocketing This Week ↗

January 26, 2023

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.

Via The Motley Fool

Expert Ratings for Pliant Therapeutics ↗

January 23, 2023

Via Benzinga

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

January 27, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

January 25, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% ↗

January 23, 2023

The company has a potentially best-in-class approach to a lung condition.

Via Investor's Business Daily

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

January 24, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

January 23, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher ↗

January 23, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The...

Via Benzinga

Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 23, 2023

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its...

Via Benzinga

Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗

January 23, 2023

Investors seem intent on leaving last week's losses behind, as earnings season heats up.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 23, 2023

Via Benzinga

Dow Jumps Over 300 Points; Crude Oil Up 1% ↗

January 23, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500...

Via Benzinga

Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis

January 23, 2023

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

Via Spotlight Growth

US Stocks Mostly Higher; Synchrony Financial Earnings Top Views ↗

January 23, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.

Via Benzinga

Why Is Xylem (XYL) Stock Down 9% Today ↗

January 23, 2023

Xylem (XYL) stock is slipping on Monday after the company revealed plans to acquire Evoqua (AQUA) in a $7.5 billion deal.

Via InvestorPlace

Why Is Ryvyl (RVYL) Stock Is On the Move Today? ↗

January 23, 2023

Ryvyl (RVYL) stock is on the move Monday after saying its prior financial data can no longer be relied on and revealing an investigation.

Via InvestorPlace

Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know ↗

January 23, 2023

What's trending on Social Media today:

Via Benzinga

Why Is Pliant Therapeutics (PLRX) Stock Up 62% Today? ↗

January 23, 2023

Pliant Therapeutics (PLRX) stock is taking off on Monday after releasing positive Phase 2a clinical trial data for bexotegrast.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 23, 2023

Via Benzinga

Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket ↗

January 23, 2023

Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 23, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday!

Via InvestorPlace

Pliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder ↗

January 23, 2023

Pliant Therapeutics Inc (NASDAQ: PLRX) has announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic...

Via Benzinga

Salesforce, Tesla And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

January 23, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

January 22, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com